Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
Authors
Keywords
-
Journal
Orphanet Journal of Rare Diseases
Volume 13, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-29
DOI
10.1186/s13023-018-0914-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis
- (2017) Aurélie Labaste et al. Journal of Cystic Fibrosis
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- (2017) Jennifer L. Taylor-Cousar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation
- (2017) Piyameth Dilokthornsakul et al. VALUE IN HEALTH
- Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States
- (2016) Abe Dunn et al. HEALTH SERVICES RESEARCH
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical and demographic factors associated with post–lung transplantation survival in individuals with cystic fibrosis
- (2015) Anne L. Stephenson et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
- (2014) Todd MacKenzie et al. ANNALS OF INTERNAL MEDICINE
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis
- (2013) Paul Tappenden et al. PHARMACOECONOMICS
- What Is Wrong with Orphan Drug Policies?
- (2012) André Côté et al. VALUE IN HEALTH
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
- (2011) Valerie Waters et al. EUROPEAN RESPIRATORY JOURNAL
- Pricing and reimbursement of orphan drugs: the need for more transparency
- (2011) Steven Simoens Orphanet Journal of Rare Diseases
- PRS18 Economic Burden of Cystic Fibrosis in the US: Costs of Care By Disease Severity and Age
- (2011) C.C. Becker et al. VALUE IN HEALTH
- Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis
- (2010) Don B. Sanders et al. PEDIATRIC PULMONOLOGY
- Incentives for orphan drug research and development in the United States
- (2008) Enrique Seoane-Vazquez et al. Orphanet Journal of Rare Diseases
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now